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A B S T R A C T
The phenolic compound 3,5-dihydroxy-4-methoxybenzyl alcohol (DHMBA) is a natural an-
tioxidant recently isolated from the Pacific oyster. DHMBA, up to a concentration of 500 µM,
has demonstrated a strong in vitro hepatocyte-protective effect from oxidative stress without
any cytotoxicity. This study investigated the in vivo potential of DHMBA-rich oyster ex-
tracts (DOE) for prevention or attenuation of non-alcoholic steatohepatitis (NASH). NASH-
model mice, developed by supplementation of a high-fat diet for 23 weeks and intravenous
injections of oxidised low-density lipoproteins, exhibited obesity, insulin resistance, hepatic
steatosis, inflammation, fibrosis, and apoptosis. These changes were significantly moder-
ated by supplementation of DOE.The search for an underlying mechanism determined that
DOE significantly improved the redox status of DNA, proteins, and lipids. Moreover, DOE sup-
pressed the increase of hepatic expression of PPARγ and CD36 (fatty acid transporter) in the
NASH-model mice. DOE might serve as a functional food for people at elevated risk for NASH.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the








The Pacific oyster (Crassostrea gigas) is a marine bivalve that
is most popular as food and is therefore important in the in-
dustry. This oyster grows and spreads quickly because of its
good tolerance against environmental pollution. From the Pacific
oyster, we isolated a novel antioxidant with a polyphenolic
structure, 3,5-dihydroxy-4-methoxybenzyl alcohol (DHMBA)
(Fig. 1A). DHMBA can inhibit copper-mediated oxidation of low-
density lipoproteins (LDL) (Watanabe, Fuda, Jin, Sakurai,
Ohkawa, et al., 2012). Furthermore, DHMBA inhibited cell mem-
brane oxidation mediated by 2,2’-azobis (2-amidinopropane)
dihydrochloride (AAPH) in hepatocyte-derived cells (C3A) more
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Fig. 1 – Effects of DHMBA-rich oyster extracts (DOE) on body weight, hepatic appearance, relative liver weight, metabolic
parameters, and hepatic enzymes. (A) Structure of DHMBA; (B) body weight; (C) hepatic appearance; (D) relative liver weight;
(E) plasma glucose level, insulin concentration and HOMA-IR; (F) liver TG, TC and FFA contents; (G) plasma TG, TC and FFA
levels; and (H) plasma AST and ALT activities. (C–H) Data obtained from 24-week-old mice. NC: mice were fed a regular
certified diet, HF−: mice were fed high-fat diet and oxidised LDL administration, HF+: mice were fed high-fat diet plus DOE
and oxidised LDL administration. Data are expressed as the mean ± SD of 8–10 mice per group. *p < 0.05, **p < 0.01,
***p < 0.001, ns: not significant (one-way ANOVA).
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effectively than hydrophilic L-ascorbic acid and chlorogenic acid,
although the oxygen radical absorbance capacity (ORAC) value
was lower for DHMBA than these hydrophilic antioxidants
(Watanabe, Fuda, Jin, Sakurai, Hui, et al., 2012). DHMBA can
inhibit AAPH-induced apoptosis and necrosis on C3A cells
without showing significant cytotoxicity up to 500 µM (Fuda
et al., 2015). Excessive hepatocyte apoptosis is regarded as one
of the pathological characteristics of NASH (Alkhouri,
Carter-Kent, & Feldstein, 2011). Taken together, these find-
ings indicate that DHMBA is a potentially useful polyphenol
for the treatment of NASH and other ROS-related diseases.
Non-alcoholic fatty liver disease (NAFLD) is one of the most
common causes of chronic liver disorders, and its prevalence
continued to increase worldwide over the last several decades.
NAFLD is associated with metabolic risk factors such as dia-
betes, obesity and dyslipidemia. NAFLD is histologically
classified as non-alcoholic fatty liver (NAFL) and NASH. The
latter can lead to cirrhosis and hepatocellular carcinoma
(Chalasani et al., 2012). The major therapeutics of NAFLD are
diet and lifestyle modification for the purpose of weight loss
(Hardy, Anstee, & Day, 2015). The sustainability of these thera-
peutic interventions, however, remains uncertain (Franz et al.,
2007). Pioglitazone is effective for the treatment of NAFLD but
is reported to increase the risk for bladder cancer (Neumann
et al., 2012). Another option is vitamin E, which is reported to
improve the histological alterations in NASH liver signifi-
cantly (Sanyal et al., 2010). However, vitamin E is reported to
increase all-cause mortality (Miller et al., 2005). Thus, there is
no established therapeutics for NASH or NAFLD, and devel-
opment of effective and safe therapeutics is required.
In spite of the accumulating evidence in vitro for the he-
patocyte protective effect of DHMBA, the in vivo effect of DHMBA
on NASH has not been studied to date. In this study, we as-
sessed the effects of DHMBA-rich oyster extracts in a novel
NASH model mouse.This mouse model was previously estab-
lished in our laboratory using the combination of a high-fat
diet (HFD) and intravenous administration of oxidised low-
density lipoproteins (oxLDL) (Yimin et al., 2012). This model
exhibits steatosis, fibrosis, intense inflammation, including
severe hepatic injury and inflammatory cell infiltration, and
characteristic hepatocellular ballooning in the liver, as well as
the change in plasma lipid and glucose metabolism.
2. Materials and methods
2.1. Chemicals
All chemicals used were of analytical grade.The following com-
pounds were obtained commercially: copper sulphate, sodium
dodecyl sulphate (SDS) and Triton X-100 (Wako Pure Chemi-
cal Industries, Ltd., Osaka, Japan), and Nonidet P-40 and Oil Red
O (Sigma-Aldrich Co., St. Louis, MO, USA).
The following kits were obtained commercially: TBARS
(thiobarbituric acid reactive substances) Assay Kit (Cayman
Chemical Co., Ann Arbor, MI, USA); Transferase CII-test Wako,
non-esterified fatty acids (NEFA) C-testWako,TG E-testWako,
Cholesterol E-test Wako, Glucose CII-test Wako (Wako Pure
Chemical Industries, Ltd.); Mercodia Ultrasensitive Mouse Insulin
ELISA Kit (Mercodia AB, Uppsala, Sweden); Absolutely RNA
Miniprep Kit (Agilent Technologies, Santa Clara, CA, USA);
SuperScript III First Strand Synthesis System for RT-PCR, Pierce
BCA Protein Assay Kit (Thermo Fisher Scientific, Carlsbad, CA,
USA); and SsoFast EvaGreen Supermix (Bio-Rad, Hercules, CA,
USA).
2.2. Oyster extracts
The oyster extracts were obtained as previously reported
(Watanabe, Fuda, Jin, Sakurai, Ohkawa, et al., 2012). Briefly,
oyster meat was boiled in water, and the resulting broth was
subsequently precipitated through the addition of 70% ethanol.
A supernatant was separated by centrifugation and collected
as the oyster extracts. The oyster extracts were lyophilised by
the Kyowac freeze-dryer (RLEII-205, Kyowa Vacuum Engineer-
ing. Co., Ltd., Tokyo, Japan), and the powdered oyster extracts
were stored at −80 °C until use.
The concentration of DHMBA was measured by liquid
chromatography/tandem mass-spectrometry and deter-
mined as 286 µg/g for the powder extracts (w/w), whereas
DHMBA was undetectable in the precipitate fraction of the
ethanol precipitation (Okabe et al., 2015). Hence, the pow-
dered extracts were nominated as DHMBA-rich oyster extracts
(DOE) in this study. The contents of protein, carbohydrate,
dietary fibre, ash, and amino acids, and minerals of DOE were
measured by Japan Food Research Laboratories (Tokyo, Japan),
and free fatty acids were measured by high-performance liquid
chromatography in our laboratory (Shrestha et al., 2015). The
compositions of DOE are summarised in Supplemental Tables S1
and S2.The major amino acid was taurine (40% of total amino
acids) (Supplemental Table S1), and the major free fatty acids
were α-linolenic acid (37% of total free fatty acids) and
docosahexaenoic acid (DHA) (32% of total free fatty acids)
(Supplemental Table S2).
2.3. Preparation of LDL and oxLDL
Blood was drawn from 4 healthy volunteers after an over-
night fast. Plasma was separated by centrifugation at 2500 rpm
for 20min at 4 °C. LDL was isolated from normal human plasma
by a sequential ultracentrifugation as described previously
(Yimin et al., 2012).The diluted LDL was incubated with copper
sulphate (0.8 g/L LDL in 20 mol/L copper sulphate) at 4 °C to
generate oxLDL. Copper sulphate was removed from oxLDL by
dialysing against phosphate-buffered saline (PBS). The purity
of LDL and oxLDL was evaluated by electrophoretic migra-
tion by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis. The final oxLDL concentration was adjusted
to 1 g protein/L.
Every volunteer provided informed consent to participate
in this study. Our experimental protocol was approved by the
ethical committee at the Faculty of Health Sciences, Hok-
kaido University (Approval No.14-76).
2.4. Mice and diets
Animal experiments were conducted according to the Regu-
lations for the Care and Use of Laboratory Animals of Hokkaido
University. Our experimental protocol was approved by the In-
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stitutional Animal Care and Use Committee (IACUC) at Hokkaido
University (Approval No. 10–0028).
Four-week-old male mice (C57BL/6J) were purchased from
Charles River Japan (Yokohama, Japan) and fed a normal chow
(MF, Oriental Yeast Co., Ltd., Tokyo, Japan) during a 7-day
acclimatisation period ad libitum.The NASHmodel mouse was
developed by a combination of a high-fat diet (HFD-60, Ori-
ental Yeast Co., Ltd., Tokyo, Japan) and intravenous injections
of oxidised LDL described previously (Yimin et al., 2012).
After acclimatisation, these mice were divided into 3 groups.
NC mice (N = 10) were fed on normal chow for 24 weeks with
intravenous injections of PBS (0.2 ml/mouse, once every 3 days,
8 times) from 21 weeks. HF− mice (N = 8) were fed on an HFD
with intravenous injections of oxLDL (0.2 ml/mouse, once every
3 days, 8 times) from 21 weeks. HF+ mice (N = 9) were fed on
an HFD supplemented with 5% (w/w) DOE with intravenous
injections of oxLDL as were the HF− mice. There was no sig-
nificant difference in the total amount of food intake between
HF+ and HF− mice.
During the experiment, the mice were fed ad libitum; their
food intake was measured twice a week, and their body weight
was measured once a week. At the end of the experiment, the
mice were anaesthetised using diethyl ether and sacrificed ac-
cording to the protocol of IACUC after fasting for 12 h.
2.5. Collection of plasma and livers
The blood samples were obtained from the axillary artery using
a heparinised syringe, and the plasma was separated by cen-
trifugation at 12,000 g for 5 min at 4 °C and stored at −80 °C until
use. Immediately after collecting blood, the liver was excised
and weighed, and then aliquoted and frozen in liquid nitro-
gen.The frozen liver sample was used for total lipid extraction,
RNA extraction and Oil Red O staining. The liver weight was
expressed as the relative liver weight (%) to the body weights.
2.6. Histological analysis of liver
The liver was frozen by liquid nitrogen immediately after sac-
rifice. Histopathological study was performed according to our
previous study (Yimin et al., 2012). To measure lipid accumu-
lation in the liver of each mouse clearly, frozen liver sections
were rinsed with distilled water, stained with 0.18% Oil Red
O with 60% 2-propanol for 15 min at 37 °C, and finally coun-
terstained with haematoxylin. The formalin-fixed specimens
were dehydrated and embedded in paraffin blocks, and tissue
sections of 2 mm were stained with haematoxylin-eosin (HE)
and Masson trichrome using standard techniques for liver mor-
phological analysis. In each experiment, sections were made
from three different areas of each liver and blindly scored by
a single pathologist by light microscopy. The histopathologi-
cal evaluation was performed on the basis of steatosis,
hepatocellular ballooning, lobular inflammation, and fibrosis
according to the standard criteria for grading of NASH, with
minor modifications (Kleiner et al., 2005).
Steatosis was evaluated on the basis of the percentage of
lipid droplet area quantified with the aid of the ImageJ soft-
ware (National Institutes of Health, Bethesda, MD, USA) in Oil
Red O-stained sections as follows: score 0, no steatosis; score
1, up to 33% steatosis; score 2, 33 to 66% steatosis; and score
3, > 66% steatosis. Hepatocyte ballooning was graded 0 to 2 on
the basis of the number of balloon cells observed on HE-
stained sections as follows: score 0, no balloon cells; score 1,
scattered balloon cells; and score 2, panacinar balloon cells.
Lobular inflammation was graded 0–3 based on inflamma-
tory foci observed on HE-stained sections as follows: score 0,
no inflammation; score 1, < 2 foci/×200 field; score 2, 2 to 4 foci/
×200 field; and score 3, >4 foci/×200 field. Fibrosis was scored
on Masson trichrome-stained sections as follows: score 0, no
fibrosis; score 1, pericellular and perivenular fibrosis; and score
2, focal bridging fibrosis.
2.7. Immunohistological analysis
Paraffin sections were also used for immunohistochemistry of
CD36; collagen type I; CD3; dityrosine; F4/80, a surface marker
of mouse macrophages; peroxisome proliferator-activated re-
ceptor γ (PPARγ); and 8-hydroxy-2’-deoxyguanosine (8-OHdG),
a marker of oxidative DNA damage and apoptosis. The sec-
tions were immunostained with rabbit anti-human CD36 (sc-
9154, Santa Cruz Biotechnologies, Inc., Dallas, TX, USA), rabbit
anti-human collagen type I (ab292, Abcam,Tokyo, Japan), rabbit
anti-human CD3 (A0452, DAKO Japan, Tokyo, Japan), rat anti-
mouse F4/80 (MCA497R, Serotec, Oxford, UK), mouse anti-
human PPARγ (sc-7273, Santa Cruz Biotechnologies, Inc.), mouse
anti-dityrosine (MDT-020P, Japan Institute for the Control of
Aging, NIKKEN SEIL Co. Ltd., Fukuroi, Japan), mouse anti-8-
OHdG (MOG-020P, Japan Institute for the Control of Aging)
followed by second antibodies with horseradish peroxidase, and
3,3’-diaminobenzidine that was used for colour develop-
ment. As a negative control, slides were incubated with normal
rabbit IgG,mouse IgG or rat IgG (Santa Cruz Biotechnology Inc.).
The In situApoptosis Detection Kit (Takara Bio Inc., Otsu, Japan)
was used for detection of apoptotic hepatocytes. Stained cells
in the sections were counted by light microscopy.
2.8. Biochemical assays
Alanine aminotransferase (ALT) and aspartate aminotransfer-
ase (AST) activities, and fasting plasma glucose and insulin
levels, were measured using commercial kits according to
manufacturer’s instructions. Insulin resistance was evalu-
ated by calculating homeostasis model assessment (HOMA-
IR) with the following formula: [fasting plasma glucose (mmol/
L) × fasting plasma insulin (mU/L) / 22.5] (Matthews et al., 1985;
Xu et al., 2005).
Total lipid was extracted from the liver according to Bligh
and Dyer (1959) withminormodification (Sugawara &Miyazawa,
2001). Briefly, each liver (approximately 50 mg) was extracted
with 1.5 mL of chloroform/methanol (2:1, v/v) using Polytron
homogeniser (Thermo Fisher Scientific Inc.,Yokohama, Japan).
The extracts were filtrated by disc filter (DISMIC-13HP,
ADVANTEC, Tokyo, Japan). Twenty microlitres of the extracts
were mixed with 10 µL of Triton X-100/methanol (1:1, v/v) and
were evaporated on the heat block at 60 °C. Distilled water
(200 µL) was added to the sample tube, and the residue was
completely solubilised at the same temperature. Total choles-
terol (TC), triacylglycerol (TG) and free fatty acid (FFA) were
determined enzymatically using commercial kits.
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Liver lipid peroxides was determined using a commercial
TBARS kit according to manufacturer’s instructions with minor
modifications. Briefly, each liver was homogenised in
radioimmunoprecipitation assay buffer [50 mM Tris-HCl,
pH 7.6, 150 mM NaCl, 1% (v/v) Nonidet P-40, 0.5% (v/v) sodium
deoxycholate, 0.1% (v/v) SDS] supplemented with Complete Pro-
teinase Inhibitor Cocktail containing EDTA (Roche Molecular
Biochemicals, Indianapolis, IN, USA) using Pellet Pestle (Sigma-
Aldrich Japan, Tokyo, Japan) at 4 °C. Cellular debris was
eliminated by centrifugation, and the supernatant was fil-
tered by the disc filter described above. Ten microlitres of the
sample was mixed with 300 µL of 10% SDS and 700 µL of the
colour reagent in the TBARS kit. The mixture was incubated
at 60 °C for 1 h, and then measured at 535 nm in a V-530 UV-
vis spectrophotometer (Jasco, Tokyo, Japan). The total protein
concentration of the cell lysate was determined using a com-
mercial dye binding assay kit.The concentration of TBARS was
normalised by the protein concentration.
2.9. RNA isolation, first strand cDNA and real-time PCR
Total RNA was isolated from the liver using a commercial kit.
The RNA samples were treated with DNase supplied by the kit.
Reverse transcription was performed using a commercial kit.
Quantification of mRNA was performed using DNA Engine
Opticon 2 System (Bio-Rad, Hercules, CA, USA) and SsoFast
EvaGreen Supermix (Bio-Rad). The primers used for real-time
PCR are described in Supplemental Table S3.Amplifications were
carried out using 0.5 µM of each primer, 2 µL of 1:5 diluted cDNA
and 10 µL SsoFast EvaGreen Supermix in a total volume of 20 µL.
The real-time PCR conditions were: after enzyme activation at
95 °C for 30 sec once; preheating denature at 95 °C for 5 sec,
annealing at 60 °C for 5 sec, extension at 72 °C for 10 sec; cycle
number, 45. EvaGreen fluorescence was detected at 72 °C at the
end of each cycle to monitor amount of PCR product formed
during the cycle.
2.10. Statistical data analysis
All data were expressed as the mean ± standard deviation (SD)
and analysed by a one-way ANOVA using Prism 5.03 (GraphPad,
San Diego, CA, USA). Significance between groups was deter-
mined using p < 0.05 confidence limits.
3. Results
3.1. Body weight, liver weight, and insulin resistance
In each study group (NC, HF−, and HF+), the increase of body
weight was observed during the experimental period.The body
weights of HF+ mice were significantly less than those of HF−
mice after 6 weeks (p < 0.05) and more evidently less after 11
weeks (p < 0.01) (Fig. 1B). The mean body weights of HF−- and
HF+ mice at 23 weeks were, respectively, 157.2% (p < 0.001) and
135.7% (p < 0.001) (NC 100%) (Fig. 1B). Accordingly, the appear-
ance of HF+ mouse looked less obese than HF− mouse (Fig. 1C).
The liver of HF+ mice had a size and a brown-colour ap-
pearance similar to that of the NC mice, whereas that of the
HF− mice showed enlargement and a pale-colour appear-
ance. The relative liver weights were increased in HF− mice
compared to NC mice 1.3-fold (p < 0.05) and decreased in HF+
mice by 28.3% (p < 0.01) of those in HF− mice at 24 weeks
(Fig. 1D).There was no significant difference in the relative liver
weights at 24 weeks between NC and HF+ mice (Fig. 1D).
The fasting plasma glucose and insulin levels of HF+ mice
were significantly lower than those of HF− mice, respectively,
23.3% (p < 0.001) and 54.0% (p < 0.01) (Fig. 1E).The HOMA-IR were
increased in HF- mice compared to NCmice 8.3-fold (p < 0.001),
and decreased in HF+ mice by 62.8% (p < 0.01) compared to those
in HF− mice at 24 weeks (Fig. 1E). There was no significant dif-
ference between NC and HF+ mice in the fasting plasma glucose,
insulin level and HOMA-IR at 24 weeks (Fig. 1E).
3.2. Histological observations
Typical histological images are shown in Fig. 2A.The lipid drop-
lets stained in red with Oil Red O were remarkably increased
in the liver of HF− mice (Fig. 2A-c), whereas the liver of NC and
HF+ mice had few droplets (Fig. 2A-a, b). Consistently, the scores
of steatosis of HF+ mice was decreased by 61.3% (p < 0.001) com-
pared to those of HF− mice at 24 weeks (Fig. 2B).
Extensive hepatocellular ballooningwas observed in the liver
of HF− mice (Fig. 2A-f), but this changewas not obvious for HF+
and NC mice (Fig. 2A-d, e). The scores of hepatocellular bal-
looning for HF+ mice was significantly decreased by 58.5%
(p < 0.001) as compared to those ofHF−mice at 24weeks (Fig. 2B).
Inflammatory focus (Fig. 2A-i, arrow), a cluster of mac-
rophages and lymphocytes, was frequently observed in the liver
of HF− mice, whereas the liver of HF+ mice had few of them
(Fig. 2A-h). The scores of inflammation were largely increased
in HF− mice, whereas the scores of HF+ mice were decreased
by 77.8% (p < 0.001) compared to those of HF− mice (Fig. 2B).
Bridging fibrosis was observed among the perivenular areas
in the liver of HF− mice (Fig. 2A-l), although in HF+ miceminimal
fibrosis was detected in each perivenular area (Fig. 2A-k). The
score of fibrosis of HF+ mice decreased by 36.6% (p < 0.01) as
compared to those of HF− mice at 24 weeks (Fig. 2B).
3.3. Lipid profiles of liver and plasma
The contents of TG, TC, and FFA of the liver were signifi-
cantly increased in HF− mice compared to NCmice, respectively,
2.9-fold (p < 0.001), 1.5-fold (p < 0.01) and 1.5-fold (p < 0.05), and
decreased in HF+ mice significantly by 42.1% (p < 0.001), 27.3%
(p < 0.05) and 42.0% (p < 0.05) as compared to those in HF− mice,
respectively (Fig. 1F).There was no significant difference in the
lipid content between NC and HF+ mice.
The contents of TG, TC, and FFA of the plasma were sig-
nificantly increased in HF− mice compared to NC mice,
respectively, 1.6-fold (p < 0.001), 2.4-fold (p < 0.001) and 1.3-
fold (p < 0.05), and decreased in HF+ mice significantly by 19.7%
(p < 0.001), 27.4% (p < 0.01) and 26.9% (p < 0.01) as compared to
those in HF− mice, respectively (Fig. 1G). There was no signifi-
cant difference in FFA between NC and HF+ mice, although there
was a significant difference in TG andTC between NC and HF+
mice.
520 J o u rna l o f Func t i ona l F ood s 2 0 ( 2 0 1 6 ) 5 1 6 – 5 3 1
3.4. Aminotransferases
Activities of hepatic enzymes,AST and ALT were increased sig-
nificantly in HF− mice compared to NC mice, respectively, 2.6-
fold (p < 0.001) and 4.9-fold (p < 0.001), and decreased in HF+
mice significantly by 50.5% (p < 0.001) and 59.2% (p < 0.001) com-
pared to those in HF− mice, respectively (Fig. 1H). There was
no significant difference in the activities of these enzymes
between NC and HF+ mice.
3.5. Hepatic inflammation
In an immunohistopathological study, the positive staining with
anti-CD3 (lymphocytes) and anti-F4/80 (macrophages) anti-
bodies was observed in the liver. The expression of CD3 and
F4/80 increased in HF− mice compared to NC mice, whereas
little staining was observed for NC and HF+ mice (Fig. 3A). The
percentage of positive cells for both anti-CD3 and anti-F4/80
antibodies was significantly increased in HF− mice compared
to NC mice, respectively, 6.5-fold (p < 0.001) and 4.9-fold
(p < 0.001), and was decreased significantly in HF+ mice by 59.6%
(p < 0.01) and 70.3% (p < 0.001) as compared to HF− mice, re-
spectively (Fig. 3B).There was no significant difference between
NC and HF+ mice for both anti-CD3 and anti-F4/80 antibodies.
Consistent with the results of immunohistopathological
study, the gene expressions of CD3 and F4/80 were signifi-
cantly increased in HF− mice compared to NCmice, respectively,
3.6-fold (p < 0.01) and 2.2-fold (p < 0.001), (Fig. 3C), and de-
Fig. 2 – Effects of DOE on liver histology and pathological scores with reference to steatosis, hepatocellular ballooning,
inflammation and fibrosis. (A) Representative photographs of liver histology. Arrow indicates inflammatory focus; and (B)
the scores of steatosis, hepatocellular ballooning, inflammation and fibrosis. ND: not detected. Scale bars = 100 µM. Data are
expressed as the mean ± SD of 8–10 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant (one-way ANOVA).
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creased significantly in HF+ mice by 71.7% (p < 0.01) and 42.0%
(p < 0.05) compared to HF− mice, respectively.
The gene expressions of tumour necrosis factor α (TNF-α)
and interleukin 6 (IL-6), that is, two major inflammatory me-
diators of macrophages,were significantly increased in HF− mice
compared to NC mice, respectively, 5.2-fold (p < 0.05) and 2.8-
fold (p < 0.05) (Fig. 4C), and decreased significantly in HF+ mice
by 80.8% (p < 0.05) and 60.8% (p < 0.05) of HF− mice, respec-
tively. There was no significant difference in the expressions
of these genes between NC and HF+ mice (Fig. 3C).
3.6. Hepatic apoptosis
The hepatic apoptosis induced by oxidative stress due to oxLDL
was evaluated using the terminal deoxynucleotidyl transfer-
ase dUTP nick end labelling (TUNEL) assay.The apoptotic cells
Fig. 3 – Effects of DOE on hepatic inflammation. (A) Representative photographs of immunohistochemistry on liver sections
for each group using anti-CD3 and anti-F4/80; (B) the percentage of positively stained area by anti-CD3 and anti-F4/80; and
(C) the gene expressions of CD3, F4/80, TNF-α and IL-6. Data are expressed as the mean ± SD of 8–10 mice per group. Scale
bars = 100 µM. *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant (one-way ANOVA).
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Fig. 4 – Effects of DOE on hepatic apoptosis. (A) Positive cell numbers in TUNEL assay on liver sections; (B) the hepatic gene
expressions of Bax, Bcl-xL, Bcl-2 and p53; (C) representative photographs of immunohistochemistry on liver sections using
anti-collagen type I; (D) the percentage of positively stained areas by anti- collagen type I; and (E) the hepatic gene
expressions of COL1a2, COL3, COL4, TGFβ-1, TIMP1 and αSMA. Data are expressed as the mean ± SD of 8–10 mice per group.
Scale bars = 100 µM. *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant (one-way ANOVA).
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were increased in HF− mice compared to NC mice 9.0-fold
(p < 0.001) and decreased in HF+ mice by 56.1% (p < 0.01) com-
pared to those in HF− mice (Fig. 4A). There was no significant
difference between NC and HF+ mice.
The results of the expressions of a pro-apoptotic gene (Bax)
gene and three anti-apoptotic genes (Bcl-xL, Bcl-2 and p53)
evaluated by real-time PCR were shown in Fig. 4B. The gene
expression of Bax was increased in HF− mice compared to NC
mice by 1.5-fold (p < 0.01) and decreased in HF+ mice by 39.1%
(p < 0.01) compared to those in HF− mice (Fig. 4B). Further-
more, the gene expression levels of Bcl-xL, Bcl-2 and p53 were
decreased in HF− mice compared to NCmice, respectively, 71.2%
(p < 0.001), 57.7% (p < 0.001), 72.7% (p < 0.001), and increased in
HF+ mice by 3.3-fold (p < 0.001), 2.5-fold (p < 0.001) and 4.1-
fold (p < 0.001) of those in HF− mice, respectively (Fig. 4B).There
was no significant difference in the expressions of these genes
between NC and HF+ mice.
3.7. Hepatic fibrosis
Hepatic fibrosis was evaluated by immunohistochemical studies
using anti-collagen type I antibody. The collagen type I ex-
pression increased in perivenular areas in HF− mice compared
to NC mice, 3.7-fold (p < 0.01), and decreased in HF+ mice by
55.9% (p < 0.05) compared to those in HF− mice (Fig. 4C and 4D).
There was no significant difference between NC and HF+ mice.
Consistently, the gene expressions of the primary prod-
ucts of fibrosis (COL1a2, COL3 and COL4) were increased in HF−
mice compared to NCmice, respectively, 6.1-fold (p < 0.001), 8.2-
fold (p < 0.01) and 2.4-fold (p < 0.05), and decreased in HF+ mice
by 60.7% (p < 0.01), 62.7% (p < 0.01) and 52.7% (p < 0.05) as com-
pared to those in HF− mice, respectively (Fig. 4E, upper). The
gene expression levels of transforming growth factor-β1 (TGF-
β1) and the tissue inhibitor of metalloproteinase 1 (TIMP1), α
smooth muscle actin (αSMA), were increased in HF− mice com-
pared to NC mice, respectively, 2.8-fold (p < 0.05), 26.3-fold
(p < 0.01) and 2.1-fold (p < 0.05), although the difference was not
statistically significant for αSMA, and decreased in HF+ mice
by 70.7% (p < 0.01), 78.3% (p < 0.05) and 64.9% (p < 0.05) com-
pared to those in HF− mice, respectively (Fig. 4E, lower). There
was no significant difference in the expressions of the above
genes between NC and HF+ mice.
3.8. Redox status
Redox status of the liver was evaluated in terms of DNA (8-
OHdG), protein (dityrosine) and lipids (TBARS). The
immunohistochemical staining of oxidative DNA (anti-8-
OHdG) and of the major targets of protein oxidation (anti-
dityrosine) were increased in HF− mice compared with NCmice,
respectively, 8.5-fold (p < 0.001) and 4.5-fold (p < 0.01), and were
decreased in HF+ mice by 54.4% (p < 0.01) and 78.3% (p < 0.01)
as compared to those in HF− mice, respectively (Fig. 5A and
5B).TBARS, lipid oxidation products, were increased in HF− mice
as compared with NC mice, 2.3-fold (p < 0.001), and decreased
in HF+ mice by 62.7% (p < 0.001) as compared with that in HF−
mice (Fig. 5B). There was no significant difference in 8-OHdG,
dityrosine and TBARS between NC and HF+ mice.
3.9. PPARγ and CD36
Immunohistochemical studies showed that the expressions of
PPARγ and CD36 were increased in HF− mice as compared to
NCmice, respectively, 4.3-fold (p < 0.001) and 59.7-fold (p < 0.001),
and decreased in HF+ mice by 78.8% (p < 0.001) and 89.7%
(p < 0.001) compared to those in HF− mice, respectively (Fig. 5C
and 5D).
Consistently, the gene expressions of PPARγ and CD36 were
increased in HF− mice compared with NC mice, respectively,
2.3-fold (p < 0.001) and 2.6-fold (p < 0.001), and decreased in HF+
mice by 38.9% (p < 0.01) and 45.7% (p < 0.01) of those in HF− mice,
respectively (Fig. 5E).There was no significant difference in the
expressions of PPARγ and CD36 between NC and HF+ mice.
4. Discussion
4.1. Multi-hit theory and our NASH model mouse
The initial hypothesis for NASH was the “two hit” theory, in
which the “first hit”was steatosis and the “second hit”was oxi-
dative stress promoting lipid peroxidation (Day & James, 1998).
More recently, overloading of fatty acids and resulting fatty-
acid-mediated lipotoxicity to hepatocytes were proposed as
promoting factors of NASH (Jou, Choi, & Diehl, 2008). Excess
of lipotoxicity was thought to cause cell death, which in turn
induced inflammation and fibrosis. Furthermore, the mul-
tiple parallel hits hypothesis was proposed, in which adipokines
and gut-derived factors were thought to play a central role (Tilg
& Moschen, 2010). It is clear that these hypotheses are over-
lapping and complementary to each other. The NASH mouse
model used in the present study was established by combi-
nation of HFD (24 weeks) and intravenous injections of oxLDL,
and therefore it can be thought that both oxidative stress and
fatty acid overloading were involved in our NASHmodel mouse.
Moreover, mice in our model exhibited a phenotype similar to
a human metabolic syndrome, such as obesity, insulin resis-
tance, and dyslipidemia, in which the involvement of adipokines
and gut-derived factors are likely to be involved.Thus, our NASH
model mouse is parallel in nature to the previous hypoth-
eses of NASH.
The use of oxLDL in NASH model mouse has not been re-
ported previously. The mice fed on the HFD without oxLDL
showed only mild hepatic steatosis and slight fibrosis in our
previous study (Yimin et al., 2012). Accordingly, HFD diet alone
is reported to take one year to induce the hepatic fibrosis (Zhou
& Xie, 2015). Thus, the oxLDL is thought to play a pivotal role
in the development of NASH in this model (Liu et al., 2013;
Walenbergh, Koek, Bieghs, & Shiri-Sverdlov, 2013), and con-
tribute to shorten the time required for the establishment of
NASH (Zhou & Xie, 2015). This idea is supported by a recent
study, which reported oxLDL as a novel risk factor for NASH
(Walenbergh et al., 2013).
4.2. NASH and hepatocellular ballooning
Histopathological observations of the liver in the NASH model
mice revealed serious hepatic steatosis, fibrosis and abnor-
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Fig. 5 – Effects of DOE on redox status and the expressions of PPARγ and CD36. (A) Representative photographs of
immunohistochemistry on liver sections using anti-8-OHdG and anti-dityrosine; (B) the percentage of positively stained
area by anti-8-OHdG and anti-dityrosine, and TBARS; (C) representative photographs of immunohistochemistry on liver
sections using anti-PPARγ and anti-CD36; (D) the percentage of positively stained areas by anti-PPARγ and anti-CD36; and (E)
the hepatic gene expression of PPARγ and CD36. Data are expressed as the mean ± SD of 8–10 mice per group. Scale
bars = 100 µM. *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant (one-way ANOVA).
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mal lipidmetabolism, as well as intense inflammation, including
advanced hepatic injury and the infiltration of inflammatory
cells, which is identical to the histological features of NASH
(Yimin et al., 2012).The hepatocellular ballooning shown in our
NASH model mouse is important in the pathogenesis of NASH
and is used to score the severity of NASH (Kleiner et al., 2005).
The ballooned cells are characteristic in large cell sizes and fre-
quent observation of Mallory-Denk bodies, but the underlying
generating mechanism is little understood. This morphologi-
cal change is thought to be related to hepatocyte injury due
to lipotoxicity (Kakisaka et al., 2012), which is included in the
previous hypothesis of NASH (Jou et al., 2008).
4.3. DHMBA for hepatocytes in vitro
Based on our previous in vitro studies, DHMBA is a potentially
useful antioxidant for NASH (Fuda et al., 2015; Watanabe, Fuda,
Jin, Sakurai, Hui, et al., 2012; Watanabe, Fuda, Jin, Sakurai,
Ohkawa, et al., 2012). Briefly, DHMBA protects hepatocyte-
derived cells (C3A) from oxidation with AAPH (Fuda et al., 2015;
Watanabe, Fuda, Jin, Sakurai, Hui, et al., 2012). Excessive he-
patocyte apoptosis is regarded as one of the pathological
characteristics of NASH (Alkhouri et al., 2011). DHMBA can
inhibit apoptosis and also necrosis on C3A cells without
showing significant cytotoxicity (Fuda et al., 2015).
4.4. DHMBA for weight loss
NASH is thought to be the hepatic manifestation of the meta-
bolic syndrome and is composed of visceral obesity,
dyslipidemia, high blood pressure and insulin resistance. In the
treatment of NASH, weight loss remains the most important
approach (Hardy et al., 2015). In this study, DHMBA success-
fully decreased the body weights of the NASH mice by 13.5%
(p < 0.01) vs. those without DHMBA supplementation (Fig. 1B).
The background mechanism of the weight reducing action of
DHMBA is not clear.
4.5. Polyphenol and obesity
Although polyphenols have not been considered necessary from
the nutrient point of view (Puupponen-Pimia et al., 2002), many
studies reported the benefits of polyphenols for health includ-
ing anti-obesity action (Baboota et al., 2013; Shahidi &
Ambigaipalan, 2015). The strengths of the weight reducing
action of polyphenols are variable in the reports including this
study: resveratrol 0 to 15% (Ahn, Cho, Kim, Kwon, & Ha, 2008;
Alberdi et al., 2013), epigallocatechin-3-gallate (EGCG) 0% to 9%
(Chen et al., 2011; Kuzu et al., 2008), curcumin 6.8% (Weisberg,
Leibel, & Tortoriello, 2008), and DHMBA 13.5% (this study) in
NASH or diabetes animal models, showing the relatively strong
power of DHMBA for weight reduction.
4.6. Polyphenol and insulin resistance
Many dietary polyphenols have antidiabetic action (Xie, Xiao,
Kai, & Chen, 2012). More than ten polyphenols are known to
have anti-α-glucosidase and anti-amylase actions (Tundis,
Loizzo, & Menichini, 2010). However, only a few studies exam-
ined blood glucose and insulin levels in NASH/NAFLD animal
models, with supplementation of polyphenols including
resveratrol (Baur et al., 2006; Kim, Jin, Choi, & Park, 2011),
curcumin, daidzein, EGCG (Bose et al., 2008), anthocyanidin (Guo
et al., 2011), and quercetin (Jeong, Kang, Choi, Kim, & Kim, 2012).
Of them, only resveratrol, EGCG and quercetin were reported
to improve insulin sensitivity. The decrease of HOMA-IR for
resveratrol, EGCG, quercetin and DHMBAwere −51 to −60% (Baur
et al., 2006; Kim et al., 2011), −76% (Bose et al., 2008), −40% (Jeong
et al., 2012), and −63% (this study), respectively. Thus, DHMBA
has significant antidiabetic potential as strong as resveratrol
and EGCG.
Oxidative stress plays a crucial role in the development of
insulin resistance (Brownlee, 2005). ROS plays a pivotal role in
the disruption of glucose-stimulated insulin secretion and
physiological control of pancreatic β cell function (Houstis,
Rosen, & Lander, 2006). The loss of β cells in Type-1 andType-2
diabetes occurs due to ROS-induced apoptosis (Butler et al., 2003;
Cnop et al., 2005). In hepatocytes and not in β cells, DHMBA
efficiently inhibited AAPH-induced apoptosis (Fuda et al., 2015).
This anti-apoptotic action of DHMBA can be attributed to its
antioxidant activity because DHMBA can effectively suppress
AAPH-induced cell membrane oxidation (Fuda et al., 2015;
Watanabe, Fuda, Jin, Sakurai, Hui, et al., 2012).Thus, it is natural
to suppose DHMBA as a major player for antiapoptotic and an-
tidiabetic action of DOE.
4.7. Polyphenol and steatosis
In this study, DOE effectively inhibited hepatic steatosis (Figs. 1D,
1F and 2). The cause of hepatic TG accumulation in NASH can
be attributed to the enhanced FFA flux to the liver via blood
vessels from adipose tissue (Browning & Horton, 2004). Con-
sistently, the expression of PPARγ, a major transcription factor
relating to cellular fatty acid uptake, and its target gene, CD36,
or fatty acid translocase, were increased in the liver in the
NAFLD patients (Fabbrini, Sullivan, & Klein, 2010) and the NASH
model mouse (Miquilena-Colina et al., 2011; Zhou et al., 2008),
suggesting increased fatty acid entry to the liver. In the present
study, DOE decreased FFA in the content in the liver (−42.0%)
and the level in plasma (−26.9%), and the expression of PPARγ
(−38.9%) and CD36 (−45.7%) in the liver vs. those without DHMBA
supplementation. FFA can translocate cytosolic CD36 to the cel-
lular membrane, enter into the cell by aid of CD36, increase
PPARγ expression, increase CD36 expression, and finally enhance
cellular FFA uptake by CD36 (Demers, Rodrigue-Way, & Tremblay,
2008; Zhou et al., 2008). Hence, it is supposed that the sup-
pression of plasma FFA by DHMBA induced the decrease of TG
content in the liver effectively through the above sequel (Fig. 6).
Many other polyphenols can attenuate hepatic steatosis in
HFD-fed mice (Aguirre, Portillo, Hijona, & Bujanda, 2014).
However, only one study has examined in vivo the effect of poly-
phenol on expression of CD36 and PPARγ, in which resveratrol
decreased their expressions in HFD-fed mice (Ahn et al., 2008).
Direct effect of polyphenols on CD36 and PPARγ expressions
has also been reported, where quercitrin, a glycoside of the fla-
vonoid quercetin, decreased the expressions of CD36 and PPARγ
in murine macrophages (J774A1) in vitro (Choi et al., 2010).These
researchers demonstrated that quercitrin attenuated the tran-
scriptional activation of PPARγ leading to CD36 induction, in
which PKCα pathway was involved. Direct effect of DHMBA on
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CD36 and PPARγ has not been examined yet, and it remains
to be addressed in the future.
4.8. Polyphenol, inflammation and apoptosis
The presence of inflammation, apoptosis, and fibrosis differ-
entiates NASH from NAFLD, although steatosis is the common
feature of both. Once the benign liver becomes subject to simple
hepatic steatosis, it becomes extremely vulnerable to a series
of hits, including oxidative damage, dysregulated hepatocyte
apoptosis, activation of the TGF-β pathway, dysregulation of
multiple adipokines, and activation of hepatic stellate cells
(HSCs), thereby leading to NASH (Tilg & Moschen, 2010; Yilmaz,
2012).
The hepatocyte apoptosis, in particular, serves as the main
cellular mechanism distinguishing between NASH and simple
steatosis (Alkhouri et al., 2011). Marcolin et al. reported that
quercetin inhibited the hepatic apoptosis by 12.3% using the
comet assay (Marcolin et al., 2013). In this study, the DHMBA-
rich extracts inhibited the hepatic apoptosis by more than 50%
by theTUNEL assay (Figs. 4A and 6). Furthermore, we have con-
firmed in vitro that DHMBA has an anti-apoptotic effect on
hepatocytes under oxidative stress (Fuda et al., 2015).Thus, the
DHMBA-rich extracts can be supposed to suppress the devel-
opment of NASH from simple steatosis by inhibiting hepatocyte
apoptosis.
The cell death via Fas signalling pathway promotes inflam-
mation (Takarada, Imanishi, Hano, & Nishio, 2003), whereas the
mechanistic linkage between apoptosis and inflammation in
the liver is unclear (Hirsova & Gores, 2015). Resveratrol, EGCG,
quercetin and curcumin are found to attenuate hepatic in-
flammation by histopathological observation (Ahn et al., 2008;
Kuo, Chang, Tsai, & Lee, 2012; Xiao et al., 2014; Ying et al., 2013),
but the underlying mechanism of anti-inflammatory action by
polyphenols was not shown in the literature. Our present study
might give information on this issue. In our NASHmousemodel,
the infiltration of macrophages (F4/80) and lymphocytes (CD3),
and the increased expressions of TNF-α and IL-6, that is, the
twomajor inflammatory mediators, were observed in the NASH
model mouse, and DOE drastically attenuated these changes
(Figs. 3 and 6).These findings suggest that the anti-inflammatory
effect of polyphenols might be mediated by their inhibitory
actions of pro-inflammatory cytokines and inflammatory cells.
4.9. Polyphenol and fibrosis
Fibrosis is a pathological change that appears in the final stage
of NASH. Liver fibrosis develops along with chronic inflam-
mation of the liver (Rosso, Chavez-Tapia, Tiribelli, & Bellentani,
2014). HSCs are thought to be the most relevant source of
hepatic myofibroblasts, which produce extracellular matrix in-
cluding collagen (Mederacke et al., 2013). The regulation of
fibrosis is very important from a therapeutic point of view.There
are a few reports that polyphenols attenuated hepatic fibro-
sis. Resveratrol, anthocyanin-rich bilberry extracts and green
tea extracts were found to attenuate NASH-associated fibro-
sis by fibrosis staining and microscopic observations by
approximately −30, −50 and −50% decreases, respectively (Di
Fig. 6 – A schematic model for the effects of DOE on the NASH mouse model. The NASH-model mice exhibited severe
obesity, insulin resistance, and steatosis, inflammation, apoptosis, and fibrosis in the liver. DOE attenuated these
pathological changes. Blue arrows indicate the effects of DHMBA-rich oyster extracts on the NASH model mouse.
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Pascoli et al., 2013; Morrison et al., 2015; Xiao et al., 2014). In
the present study, fibrosis was examined extensively not only
through pathological observations (fibrosis and collagen
stainings) but also through analysis of the expression of
fibrosis-related genes, such as collagens I, III, and IV, TGF-β1,
TIMP1, and αSMA, that is a HSCs’ activation marker. All of
these markers were decreased by DOE (Fig. 6). Further,
DOE effectively attenuated the hepatic fibrosis by 56%
immunohistopathologically. Although this anti-fibrotic effect
is a direct action for HSCs or an indirect effect through anti-
apoptotic and anti-inflammatory actions, DOE can be thought
to have a profound inhibitory effect on each pathological
process involved in the progression of NASH.
4.10. Other minor components of DOE
Despite that our oyster extracts are rich in DHMBA, it may be
possible that otherminor elements can also contribute to patho-
physiology in NASH model mouse.
In our previous study, we screened 11 non-flavonoid anti-
oxidants (caffeic acid, DHMBA, dithranol, ferulic acid, gallic acid,
gentisic acid, hydroxytyrosol, matairesinol, phloridzin,
resveratrol, and secoisolariciresinol) and 13 flavonoid antioxi-
dants (apigenin, catechin, cyanidin, epigallocatechin, eriodictyol,
daidzein, genistein, kaempferol, luteolin, malvidin, naringenin,
quercetin, and taxifolin) in DOE by high-resolution mass
spectrometry (Fuda et al., 2015).We found DHMBA as the pre-
ponderant polyphenol, and also gentisic acid,matairesinol, and
daidzein as only trace constituents.
Among the detected amino acids in DOE, taurine was found
to be the major component (Supplemental Table S1). It is re-
ported that taurine attenuated hepatic steatosis, inflammation,
insulin resistance in NASH/NAFLD model mice (Chang et al.,
2011; Gentile et al., 2011). Further, taurine is reported to have
anti-obesity action in two obesity animal models, the Otsuka
Long-EvansTokushima Fatty rat (Nakaya et al., 2000) and high-
fat diet mouse (Tsuboyama-Kasaoka et al., 2006), which are not
NASHmodels. In spite of the reported actions of taurine similar
with those of DOE, it is unlikely that the action of DOE was
caused solely by taurine.The dose of taurine in our study was
calculated to be 4.9 mg/g diet, which was 10 times lower than
the reported dose of taurine effective in the above obesity
animal models (50 mg/g diet).
We detected polyunsaturated fatty acids (PUFAs), particu-
larly DHA and α-linolenic acid, as major fatty acid components
in DOE (Supplemental Table S2). There is no report that
α-linolenic acid affects NASH/NAFLD model mouse.
Eicosapentaenoic acid (EPA) and DHA, however, are known to
attenuate hepatic steatosis, inflammation, oxidative stress and
fibrosis in a NASH/NAFLD model mouse (Pan, Lai, Tsai, & Ho,
2014), although they had no effect on obesity in the similar
models (Depner, Philbrick, & Jump, 2013; Ishii et al., 2009). On
the other hand, in this study, DOE attenuated obesity as well
as insulin resistance quite effectively. In addition, the doses
of EPA (Kajikawa, Harada, Kawashima, Imada, & Mizuguchi,
2009) and DHA (Kim, Lee, Park, Jeon, & Choi, 2008) reported to
be effective in NASH model mice were 38–50 mg/g diet, which
is 4 orders of magnitude larger than the total dose of EPA plus
DHA in our study (4.08 µg/g diet).
Taking all together, each of PUFAs and taurine in DOE cannot
solely explain the profound and wide effects of DOE in NASH
model mouse. A possible mechanistic explanation is that
DHMBA in DOE played a predominant role while PUFAs and
taurine served as minor players. Another possibility is that
DHMBA together with PUFAs, taurine, and yet unidentified pos-
sible components, collectively exerted a protective effect against
the pathological changes in NASH model mouse. In our future
study,we will address the effect of purified DHMBA on the same
animal model, which might elucidate yet unclear mecha-
nism of the in vivo effect of DOE in our NASH model mouse.
5. Conclusion
In conclusion, DOE might be a potentially useful agent to at-
tenuate pathological changes in NASH. The limitation of this
study is the lack of specification of active components in DOE.
DHMBA might be one of the most likely candidates, but we
cannot rule out the collective effect of a number of constitu-
ents, including DHMBA, PUFAs, taurine, and yet unidentified
components of DOE.
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